

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)										APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	CLASS	SUB-CLASS	CLASS	SUB-CLASS	CLASS	SUB-CLASS	CLASS	SUB-CLASS	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
SH	AA	5	9	3	9	4	2	2	8/17/99	Cavalla et al.	544	277	
	AB	5	8	6	4	0	3	7	1/26/99	Chasin et al.	544	277	
	AC	5	6	3	1	2	6	0	5/20/97	Belardinelli et al.	514	263	
	AD	5	4	9	6	8	5	3	3/5/96	Shiota et al.	514	469	
	AE	5	4	7	0	5	7	9	11/28/95	Bonte, et al.	424	450	
	AF	5	4	4	7	9	3	3	9/5/95	Suzuki, et al.	514	263	
	AG	5	4	3	4	1	5	0	7/18/95	Austel, et al.	514	228.5	
	AH	5	4	2	2	3	5	0	6/6/95	Woolf	514	252	
	AI	5	3	3	4	5	9	6	8/2/94	Hartman, et al.	514	301	
SH	AJ	5	3	2	2	8	4	7	6/21/94	Marfat et al.	514	303	

FOREIGN PATENT DOCUMENTS														
EXAMINER INITIAL	CLASS	SUB-CLASS	CLASS	SUB-CLASS	CLASS	SUB-CLASS	CLASS	SUB-CLASS	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
													YES	NO
SH	AK	9	7	4	9	7	0	2	12/31/97	WO	C07D	403/04		
SH	AL	9	7	1	2	8	8	8	4/10/97	WO	C07D	473/00		
SH	AM	9	7	1	2	8	8	7	4/10/97	WO	C07D	473/00		
SH	AN	9	6	3	6	6	3	8	11/21/96	WO	C07D	473/06		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
SH	AO	Shimada, Chem. Abstracts 124:85064a (1996).
	AP	Li, Chem. Abstracts 124:46754 (1996).
	AQ	Glösenkamp, et al., "Tautomer-Specific Anti-(N-3-Substituted)-Adenine Antibodies: New Tools in", Angew. Chem. Int. Ed. Engl., 32, No. 11, pp. 1640-1641 (1993).
	AR	"Novel phosphodiesterase inhibitors for the therapy of asthma", Theodore J. Torphy, George P. Livi and Siegfried B. Christensen, DN&P 6(4), May 1993 pp. 203-214.
SH	AS	"Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle", Theodore J. Torphy, Bradley J. Undem, Lenora B. Cieslinski, Mark A. Luttmann, Martin L. Reeves and Douglas W.P. Hay, The Journal of Pharmacology and Experimental Therapeutics, 1993, Vol. 265, No. 3, 1213-1223.

EXAMINER <i>Van Houten</i>	DATE CONSIDERED <i>4/19/02</i>
----------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146					
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)														APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614					

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	CLASS	SUB-CLASS	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE						
SH	BA	5	3	0	0	2	9	8	4/5/94	LaNoue	424	442	
	BB	5	2	9	0	7	8	2	3/1/94	Suzuki, et al.	514	263	
	BC	5	2	6	4	5	8	9	11/23/93	Corey	548	51	
	BD	5	2	0	6	2	5	5	4/27/93	Ubasawa et al.	514	374	
	BE	5	1	9	0	9	4	2	3/2/93	Poss	514	235.8	
	BF	5	1	7	7	0	7	4	1/5/93	Allen et al.	514	234	
	BG	5	1	7	5	2	9	1	12/29/92	Kufner-Muhl	544	267	
	BH	5	1	7	5	2	9	0	12/29/92	Rzeszutowski, et al.	544	267	
	BI	5	1	3	9	9	2	1	8/18/92	Takagi, et al.	430	264	
SH	BJ	5	1	1	7	8	3	0	6/2/92	McAfee, et al.	128	654	

FOREIGN PATENT DOCUMENTS														
CLASS	SUB-CLASS	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION								
YES	NO													
SH	BK	0	6	7	5	1	2	4	10/04/95	EP	C07D	473/30		
	BL	9	5	2	3	1	4	8	8/31/95	WO	C07D	473/06		
	BM	9	5	2	0	5	8	9	8/3/95	WO	C07D	473/04		
	SH	BN	9	5	0	0	5	1	6	1/5/95	WO	C07D	473/34	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
SH	BO	"The PDE IV family of calcium-independent phosphodiesterase enzymes", John A. Lowe III and John B. Cheng, Drugs of the Future, 1992, 17(9): 799-807.
SH	BP	"Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?", Mark A. Gienbycz, Biochemical Pharmacology, 1992, vol. 43, No. 10 pp. 2041-2051.
SH	BQ	Ogawa et al. Synthesis and Biological Activity of Hypoxanthine 7-N-Oxide and Related Compounds, Chem Pharm. Bull. 40(3), 612-616 (1992).
SH	BR	Bender, Chem. Abstracts 116: 255335 (1992).
SH	BS	"Differential modulation of tissue function and therapeutic potential selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", C. David Nicholson, R.A. John Chaliss and Mohammed Shahid, 1991, Elsevier Science Publishers Ltd. (UK), TIPS 12:19-27.

EXAMINER <i>Pankaj</i>	DATE CONSIDERED <i>4/19/02</i>
------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)										APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE	
SH	CA	5			1	1	0	8	1	8	5/5/92	Allgeier	514	261
	CB	5			0	9	1	4	3	1	2/25/92	Tulshian, et al.	514	262
	CC	5			0	6	8	2	3	6	11/26/91	Suzuki et al.	514	263
	CD	5			0	5	7	5	1	7	10/15/91	Johnston et al.	514	254
	CE	5			0	4	7	4	1	1	9/10/91	Takasugi et al.	514	300
	CF	5			0	1	0	0	8	1	4/23/91	Hofer	514	263
	CG	4			9	8	8	6	8	9	1/29/91	Janssens, et al.	514	212
	CH	4			9	8	1	8	5	7	1/1/91	Daluge et al.	514	263
	CI	4			9	7	1	9	7	2	11/20/90	Doll, et al.	514	265
SH	CJ	4			9	6	5	1	6	9	10/23/90	Hirano, et al.	430	264

FOREIGN PATENT DOCUMENTS														
EXAMINER INITIAL	CLASS	SUB-CLASS	TRANSLATION	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
SH	CK	9			4	2	4	1	3	3	10/27/94	WO	C07D	473/06
	CL	9			4	2	2	8	5	9	10/13/94	WO	C07D	471/04
	CM	0			6	1	9	3	1	6	10/12/94	EP	C07D	473/04
SH	CN	9			4	2	0	4	6	0	9/15/94	WO	C07D	207/02

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)													
EXAMINER INITIAL	CLASS	REFERENCE											
SH	CO	"Phosphodiesterase inhibitors: new opportunities for the treatment of asthma", Theodore J. Torphy, Bradley J. Undem, <u>Thorax</u> 1991; 46:512-523.											
	CP	Reitz, et al., "Conformational Study of N-Substituted Adenines by Dynamic Proton NMR: Relatively...", J. Org. Chem. 1990, 55, 5761-5766, pp. 5761-5766.											
	CQ	Ronald E. Weishaar, et al., Subclasses of Cyclic GMP-Specific phosphodiesterase and their role in regulating the effects of atrial natriuretic factor, Dept. Of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co. Hypertension, Vol. 15, No. 5, May 1990.											
	CR	Naruto, Chem. Abstracts 114: 246982 (1990).											
SH	CS	K. A. Jacobson, et al., "Sulfur-Containing 1,3-Dialkylxanthine Derivatives as Selective Antagonists at A ₁ -Adenosine Receptors", J. Med. Chem. 1989, Vol. 32, pp. 1873-1879.											

EXAMINER <i>Paul H. H.</i>	DATE CONSIDERED <i>4/19/02</i>
----------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)										APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL										DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SH	DA	4	9	2	5	8	4	7		5/15/90	Hofer	514	263	
	DB	4	8	8	3	8	0	1		11/28/89	Nathanson	514	263	
	DC	4	8	6	8	1	8	3		9/19/89	Kanai et al.	514	255	
	DD	4	8	5	1	3	2	1		7/25/89	Takagi, et al.	430	264	
	DE	4	8	3	1	1	5	2		5/16/89	Itoh et al.	548	224	
	DF	4	8	0	3	2	1	6		2/7/89	Appleton et al.	514	407	
	DG	4	7	6	9	3	7	7		9/6/88	Snyder, et al.	514	263	
	DH	4	7	5	5	5	1	7		7/5/88	Bruns, et al.	514	263	
	DI	4	7	1	0	5	0	3		12/1/87	Hofer	514	263	
SH	DJ	4	6	8	4	6	5	6		8/4/87	Atwal	514	274	

FOREIGN PATENT DOCUMENTS															
										DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
														YES	NO
SH	DK	9	4	2	0	4	5	5		9/15/94	WO	CO7C	255/36		
	DL	9	4	2	0	4	4	6		9/15/94	WO	CO7C	43/235		
	DM	6	2	1	1	8	5	6		8/2/94	Japan	CO7D	473/06		
SH	DN	9	4	1	4	8	0	0		7/7/94	WO	CO7D	405/06		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
SH	DO	Cambridge Dictionary of Science and Technology, pp. 23-24 (1988).
	DP	"Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes from cardiac muscle, arterial and airway smooth muscle", Paul J. Silver, Linda T. Hamel, Mark H. Perrone, Ross G. Bently, Cynthia R. Bushover and Dale B. Evans, European Journal of Pharmacology, 150 (1988) 85-94, Elsevier.
	DQ	Beecham, Chem. Abstracts 106:27814n (1987).
	DR	Ronald E. Weishaar, et al., Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets, Biochemical Pharmacology, Vol. 35, No. 5, pp. 787-800, 1986.
SH	DS	Itaya et al, 3-Methylinosine, Chem. Pharm. Bull, 33(6), 2213-19 (1985).

EXAMINER <i>Parker</i>	DATE CONSIDERED <i>4/19/02</i>
------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)										APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL										DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
SH	EA	4	6	5	2	6	5	4		3/24/87	Verga et al.	548	217	
	EB	4	6	1	6	0	2	0		10/7/86	Furrer, et al.	514	264	
	EC	4	4	6	9	6	9	8		9/4/84	Philipossian et al.	424	253	
	ED	4	4	5	4	1	3	8		6/12/84	Goring	424	253	
	EE	4	4	1	6	8	9	2		11/22/83	Dawson	424	272	
	EF	R	e	3	1	4	2	9		10/25/83	Tull, deceased et al.	544	277	
	EG	4	4	0	7	8	0	2		10/4/83	Graham, et al.	424	253	
	EH	4	3	6	1	6	9	9		11/30/82	Rasmusson	544	277	
	EI	4	3	0	8	2	7	8		12/29/81	Schneider et al	424	273	
	SH	EJ	4	2	4	1	0	6	3		12/23/80	Naito, et al.	424	253

FOREIGN PATENT DOCUMENTS															
										DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
														YES	NO
SH	EK	9	4	1	4	7	4	2		7/7/94	WO	CO7C	43/253		
	EL	9	4	1	2	4	6	1		6/9/94	WO	CO7C	65/21		
	EM	9	4	1	0	1	1	8		5/11/94	WO	CO7C	43/235		
SH	EN	0	5	9	0	9	1	9		4/6/94	EP	C07D	473/06		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
SH	EO	Nagarajan, Chem. Abstracts 103: 37354 (1985).
SH	EP	"The pharmacology and therapeutic use of theophylline", Miles Weinberger, M.D., The Journal of Allergy and Clinical Immunology, Vol. 73, Number 5, Part 1, 525-544 (1984).
	EQ	Isomura et al., "Studies on the synthesis and anti-inflammatory activity of 2,6-Di-tert-butylphenols with a heterocyclic group at the 4-position.I". Vol. 31, No. 9, pp. 3168-3178 (1983).
	ER	Itaya, Tetrahedron Letters, Vol. 23, No. 21, pp. 2203-2204 (1982).
SH	ES	"Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme", W. Joseph Thompson, Wesley L. Terasaki, Paul M. Epstein, Samuel J. Strada, Advances in Cyclic Nucleotide Research, Vol. 10, 1979, pp. 69-92.

EXAMINER <i>Parthasarathy</i>	DATE CONSIDERED <i>4/19/02</i>
-------------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)										APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL										DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SH	FA	4	2	3	3	3	0	3		11/11/80	Bergstrand, et al.	424	253	
	FB	4	1	6	7	6	2	8		9/11/79	Kormany	542	454	
	FC	4	1	0	7	3	0	6		08/15/78	Voorhees	424	248.51	
	FD	4	0	2	5	6	3	7		5/24/77	Dunwell	424	272	
	FE	4	0	2	5	6	3	6		5/24/77	Dunwell et al.	424	269	
	FF	3	9	6	2	4	5	2		6/8/76	Evans et al.	424	272	
	FG	3	9	2	3	8	3	3		12/2/75	Gruenman et al	260	340.5	
	FH	3	7	0	6	8	3	4		12/19/72	Scheilenbaum et al.	424	272	
	FI	3	6	7	4	7	8	1		7/4/72	Schinzel et al.	260	240	
SH	FJ	3	6	3	6	0	3	9		1/18/72	Gruenman et al	260	309.7	

FOREIGN PATENT DOCUMENTS															
										DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
														YES	NO
SH	FK	9	4	0	3	4	5	6		2/17/94	WO	C07D	473/06		
	FL	9	4	0	2	4	6	5		2/3/94	WO	C07D	213/75		
	FM	9	3	2	5	5	1	7		12/23/93	WO	C07C	233/75		
SH	FN	9	3	1	9	7	4	7		10/14/93	WO	A61K	31/275		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
SH	FO	T. Fuji, et al. "3-Substituted Adenines. In Vitro Enzyme Inhibition and Antiviral Activity", Journal of Medical Chemistry, 1979, Vol. 22, No. 2.
	FP	CA 116:173893, (1979) Girshovich.
	FQ	Pirisino, Chem. Abstracts 92:6207 (1977).
	FR	Ninomiya, Chem. Abstracts 88: 51054 (1977).
	SH	FS

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>4/19/02</i>
-----------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUN 29 2001

TECH CENTER 1600/2900

Sheet 7 of 10

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)										APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL										DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SH	GA	3	5	9	0	0	2	9		6/29/71	Koch, et al.	260	211.5	
	GB	3	5	7	4	2	1	8		4/6/71	Hideg et al.	260	293.4	
	GC	3	5	4	1	1	0	0		11/17/70	Ramirez et al.	260	286	
	GD	3	4	9	4	9	1	9		2/10/70	Collins et al.	260	240	
	GE	3	2	6	2	9	2	9		7/26/66	Okubu et al.	260	240	
	GF	3	2	2	5	0	4	6		12/21/65	Zwahlen	260	252	
	GG	3	2	1	5	6	9	6		11/2/65	Denayer	260	252	
	GH	3	1	3	6	7	7	1		6/9/64	Liechti et al.	260	296	
	GI	3	1	3	5	7	5	3		6/2/64	Hitchings, et al.	260	252	
	SH	GJ	3	0	7	9	3	7	8		2/26/63	Schroeder, et al.	260	211.5

FOREIGN PATENT DOCUMENTS															
										DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
														YES	NO
SH	GK	9	3	1	5	0	4	5		8/5/93	WO	C07C	237/22		
	GL	9	3	1	5	0	4	4		8/5/93	WO	C07C	237/22		
	GM	9	3	1	4	0	8	2		7/22/93	WO	C07D	401/04		
SH	GN	9	3	1	4	0	8	1		7/22/93	WO	C07D	401/04		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
SH	GO	Database CAPLUS on STN, hadassah Med. Sch., Hebrew Univ., (Jerusalem, Israel), No. 1977:67403, Bergmann, F., et al., "Influence of 8-substituents on the oxidation of hypoxanthine and 6-thioxopurine by bovine milk xanthine oxidase," Abstract to Biochem. Biophys. Acta 480(1), pp. 39-46, 1977.
	GP	Enoki, Chem. Abstracts 85:5692 (1976).
	GQ	Enoki, Chem. Abstracts 84:180299 (1976).
	GR	Kazimierczd, Chem. Abstracts 82:125358x (1975).
SH	GS	"Controlled Interaction between Nucleic Acid Bases. Intramolecular Stacking Interactions between Two Adenine Rings", Nelson J. Leonard et al.; Journal of the American Chemical Society, 95:12, Jun. 13, 1973, pp. 4010-4016.

EXAMINER <i>Parham</i>	DATE CONSIDERED <i>4/19/02</i>
------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUN 29 2001

Sheet 8 of 10

TECH CENTER 1600/2900

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)										APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL										DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
SH	HA	2	9	6	6	4	8	8		12/27/60	Shive, et al.	260	252	
	HB	2	9	5	7	8	7	5		10/25/60	Lyttle, et al.	260	252	
	HC	2	9	5	6	9	9	8		10/18/60	Baizer	260	252	
	HD	2	9	0	3	4	5	5		9/8/59	Strong	260	252	
	HE	2	8	4	4	5	7	7		7/22/58	Acker	260	254	
SH	HF	2	6	9	1	6	5	4		10/12/54	Hitchings, et al.	260	247.5	

FOREIGN PATENT DOCUMENTS															
										DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
														YES	NO
SH	HG	5	1	0	5	6	3	1		4/27/93	Japan	A61K	31/52		
	HH	9	3	0	7	1	1	1		4/15/93	WO	CO7C	49/753		
	HI	0	5	3	6	7	1	3		4/14/93	EP	CO7D	263/34		
	HJ	0	5	5	9	0	5	6		3/9/93	Japan	CO7D	473/22		
	HK	9	2	1	9	5	9	4		11/12/92	WO	CO7D	207/26		
SH	HL	0	5	1	1	8	6	5		11/4/92	EP (A1)	CO7D	231/08		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
SH	HM	G.T. Rogers, et al. "Synthesis of 3-Methylisoguanine [6-Amino-3-methylpurin-2(3H)-one], J. Chem. Soc. (C), 1971, pp. 2364-2366.
	HN	Database CAPLUS on STN, Hadassah Me. Sch., Heb. Univ., (Jerusalem, Israel), No. 1971:435951, Bergmann, F., et al., "Methylation of 6-(methylthio)-8-phenylpurines," Abstract to J. Chem. Soc. (10), pp. 1822-1829, 1971.
	HO	Seita, Chem. Abstracts 76:25649a (1971).
	HP	"The Synthesis of Some 6 Thioxanthines", K.R.H. Wooldrige and R. Slack, J. Chem. Soc. 1962, Annex IV:1863-1868.
	HQ	"Structure-Activity Relationships in a Series of 6-Thioxanthines with Bronchodilator and Coronary Dilator Properties", A.K. Armitrage, Janet Boswood and B.J. Large, Brit. J. Pharma. 1961, 17:196-207.
	HR	J.A. Montgomery, et al. "Synthesis of Potential Anticancer Agents...", Vol. 81, pp. 3963-3967 (1959).
	HS	Elion, Ciba Foundation Symp., Chem and Biol. Purines, pp. 39-49 (1957).
SH	HT	Elion, Chem. Abstracts 53:6243 (1957).

EXAMINER <i>Parker</i>	DATE CONSIDERED <i>4/19/02</i>
------------------------	--------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO. 332.1106		SERIAL NO. 09/636,146	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)										APPLICANTS Mark CHASIN, et al.			
										FILING DATE August 10, 2000		GROUP 1614	

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	1	2	3	4	5	6	7	8	9	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	IA													

FOREIGN PATENT DOCUMENTS															
	1	2	3	4	5	6	7	8	9	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
														YES	NO
SH										8/5/92	EP (A1)	C07C	235/36		
										4/2/92	WO	C07D	473/06		
										4/2/92	WO	C07D	473/06		
										2/12/92	EP (A1)	C07C	271/60		
										7/3/91	EP	C07D	473/04		
										3/20/91	EP	C07D	487/14		
										3/6/91	EP	C07D	473/06		
										1/24/91	WO	C07D	233/60		
										9/26/90	EP	C07D	473/06		
										9/12/90	EP	C07D	473/04		
										9/12/90	EP	C07D	473/04		
										5/23/90	EP	C07D	473/06		
										11/29/89	EP(A2)	A61K	31/41		
										10/27/89	NZ	C07D	473/00		
										6/20/89	Japan	C07D	473/06		
										7/28/88	WO	A61K	37/02		
										3/2/88	EP	C07D	473/06		
										2/24/88	EP	C07D	473/22		
SH										11/5/87	WO	C07C	47/11		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)													
	IU												
EXAMINER <i>Pan</i>										DATE CONSIDERED <i>4/19/02</i>			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
332.1106SERIAL NO.
09/636,146

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANTS
Mark CHASIN, et al.FILING DATE
August 10, 2000GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL									DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	JA												

FOREIGN PATENT DOCUMENTS

									DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
SH	JB	0	2	0	3	7	2	1	12/03/86	EP	C07D	473/06		
	JC	0	1	9	1	3	1	3	8/20/86	EP	C07D	473/22		
	JD	8	7	0	6	5	7	6	4/29/86	WO	C07D	47/11		
	JE	0	1	7	8	4	1	3	4/23/86	EP (A1)	C07D	235/18		
	JF	8	6	0	1	7	2	4	3/27/86	WO	A61L	9/04		
	JG	2	0	9	1	2	4	9	7/28/82	UK	A61K	31/52		
	JH	5	7	2	1	3	7	5	2/4/82	JP	C07D	235/18		
	JI	1	5	8	0	7	8	2	12/3/80	Great Britain	C07D	473/06		
	JJ	0	0	1	8	1	3	6	10/29/80	EP	C07D	473/22		
	JK	2	0	4	1	3	5	9	9/10/80	Great Britain	C07D	473/34		
	JL	1	5	6	1	0	0	5	2/13/80	Great Britain	C07D	473/28		
	JM	1	4	9	8	7	0	5	1/25/78	Great Britain	C07D	207/26		
	JN	5	1	5	4	5	8	7	5/13/76	JP	C07D	4/3.02		
	JO	1	5	4	8	2	5	2	12/06/68	FR	C07D	A61K		
	JP	1	0	7	7	6	8	9	8/2/67	Great Britain	C07D	57/38		
SH	JQ	0	8	3	5	8	1	8	2/20/61	France	A61K	C07D		
	JR													
	JS													

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	JT	
EXAMINER	<i>Parhupth</i>	DATE CONSIDERED 4/19/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.